These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25671083)

  • 1. Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia.
    Vallortigara J; Rangarajan S; Whitfield D; Alghamdi A; Howlett D; Hortobágyi T; Johnson M; Attems J; Ballard C; Thomas A; O'Brien J; Aarsland D; Francis P
    F1000Res; 2014; 3():108. PubMed ID: 25671083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia.
    Alghamdi A; Vallortigara J; Howlett DR; Broadstock M; Hortobágyi T; Ballard C; Thomas AJ; O'Brien JT; Aarsland D; Attems J; Francis PT; Whitfield DR
    J Alzheimers Dis; 2017; 57(2):373-386. PubMed ID: 28269775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?
    Jellinger KA
    Parkinsonism Relat Disord; 2022 Jul; 100():24-32. PubMed ID: 35691178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    Jellinger KA
    J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease.
    Enache D; Pereira JB; Jelic V; Winblad B; Nilsson P; Aarsland D; Bereczki E
    J Alzheimers Dis; 2020; 77(3):1143-1155. PubMed ID: 32925049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment.
    Whitfield DR; Vallortigara J; Alghamdi A; Howlett D; Hortobágyi T; Johnson M; Attems J; Newhouse S; Ballard C; Thomas AJ; O'Brien JT; Aarsland D; Francis PT
    Neurobiol Aging; 2014 Dec; 35(12):2836-2844. PubMed ID: 25104558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of pathological markers in Parkinson's disease dementia post-mortem brains compared to dementia with Lewy bodies.
    Tu H; Zhang ZW; Qiu L; Lin Y; Jiang M; Chia SY; Wei Y; Ng ASL; Reynolds R; Tan EK; Zeng L
    BMC Neurosci; 2022 Jan; 23(1):3. PubMed ID: 34983390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
    Jellinger KA; Korczyn AD
    BMC Med; 2018 Mar; 16(1):34. PubMed ID: 29510692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathological and clinical comparison of Parkinson’s disease dementia and dementia with Lewy bodies].
    Bencs V; Bencze J; Módis VL; Simon V; Kálmán J; Hortobágyi T
    Orv Hetil; 2020 May; 161(18):727-737. PubMed ID: 32338488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias.
    Datta A; Chai YL; Tan JM; Lee JH; Francis PT; Chen CP; Sze SK; Lai MKP
    Mol Brain; 2017 Aug; 10(1):36. PubMed ID: 28800743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias.
    Howlett DR; Whitfield D; Johnson M; Attems J; O'Brien JT; Aarsland D; Lai MK; Lee JH; Chen C; Ballard C; Hortobágyi T; Francis PT
    Brain Pathol; 2015 Jul; 25(4):401-8. PubMed ID: 25103200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
    Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
    J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson's disease dementia.
    Hansen D; Ling H; Lashley T; Foley JA; Strand C; Eid TM; Holton JL; Warner TT
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):143-156. PubMed ID: 32720329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Transforming Growth Factor β2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Aβ42 Load.
    Chong JR; Chai YL; Lee JH; Howlett D; Attems J; Ballard CG; Aarsland D; Francis PT; Chen CP; Lai MK
    J Alzheimers Dis; 2017; 56(1):157-166. PubMed ID: 27911312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration.
    Chai YL; Chong JR; Weng J; Howlett D; Halsey A; Lee JH; Attems J; Aarsland D; Francis PT; Chen CP; Lai MKP
    Brain Pathol; 2019 Jan; 29(1):63-74. PubMed ID: 30051532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders.
    Irwin DJ; Hurtig HI
    J Alzheimers Dis Parkinsonism; 2018; 8(4):. PubMed ID: 30473927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort.
    Kramberger MG; Auestad B; Garcia-Ptacek S; Abdelnour C; Olmo JG; Walker Z; Lemstra AW; Londos E; Blanc F; Bonanni L; McKeith I; Winblad B; de Jong FJ; Nobili F; Stefanova E; Petrova M; Falup-Pecurariu C; Rektorova I; Bostantjopoulou S; Biundo R; Weintraub D; Aarsland D;
    J Alzheimers Dis; 2017; 57(3):787-795. PubMed ID: 28304294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No Significant Difference in Cognitive Decline and Mortality between Parkinson's Disease Dementia and Dementia with Lewy Bodies: Naturalistic Longitudinal Data from the Swedish Dementia Registry.
    Fereshtehnejad SM; Lökk J; Wimo A; Eriksdotter M
    J Parkinsons Dis; 2018; 8(4):553-561. PubMed ID: 30103351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease.
    Joki H; Higashiyama Y; Nakae Y; Kugimoto C; Doi H; Kimura K; Kishida H; Ueda N; Nakano T; Takahashi T; Koyano S; Takeuchi H; Tanaka F
    J Neurol Sci; 2018 Feb; 385():99-104. PubMed ID: 29406924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia.
    Vallortigara J; Whitfield D; Quelch W; Alghamdi A; Howlett D; Hortobágyi T; Johnson M; Attems J; O'Brien JT; Thomas A; Ballard CG; Aarsland D; Francis PT
    J Alzheimers Dis; 2016; 50(1):101-10. PubMed ID: 26639969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.